Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Oteyza JP, Herrera P, Barragan E, Montesinos P, Vela JAG, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R.

Haematologica. 2019 Feb;104(2):288-296. doi: 10.3324/haematol.2018.194712. Epub 2018 Aug 9.

2.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. No abstract available.

3.

Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report.

Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J.

J Oncol Pharm Pract. 2019 Jun;25(4):998-1002. doi: 10.1177/1078155218769367. Epub 2018 Apr 24.

PMID:
29690814
4.

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ.

Leukemia. 2017 Jun;31(6):1446-1449. doi: 10.1038/leu.2017.58. Epub 2017 Feb 17. No abstract available.

5.

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.

Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, Barrio S, Sanchez ML, Alignani D, Lasa M, García de Coca A, Pardal E, Oriol A, Garcia ME, Escalante F, González-López TJ, Palomera L, Alonso J, Prosper F, Orfao A, Vidriales MB, Mateos MV, Lahuerta JJ, Gutierrez NC, San Miguel JF.

Blood. 2016 Jun 16;127(24):3035-9. doi: 10.1182/blood-2015-10-673095. Epub 2016 Apr 11.

PMID:
27069257
6.

The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.

Soler G, Bernal-Vicente A, Antón AI, Torregrosa JM, Caparrós-Pérez E, Sánchez-Serrano I, Martínez-Pérez A, Sánchez-Vega B, Vicente V, Ferrer-Marin F.

Ann Hematol. 2015 May;94(5):789-94. doi: 10.1007/s00277-014-2266-y. Epub 2014 Dec 9.

PMID:
25482455
7.

Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.

Cascales A, Pastor-Quirante F, Sánchez-Vega B, Luengo-Gil G, Corral J, Ortuño-Pacheco G, Vicente V, de la Peña FA.

Oncologist. 2013;18(4):446-53. doi: 10.1634/theoncologist.2012-0239. Epub 2013 Apr 10.

8.

Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.

Tello-Montoliu A, Jover E, Marín F, Bernal A, Lozano ML, Sánchez-Vega B, Pastor FJ, Hurtado JA, Valdés M, Vicente V, Rivera J.

Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):219-26. doi: 10.1016/j.recesp.2011.07.013. Epub 2011 Nov 23. English, Spanish.

PMID:
22116003
9.

Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation.

Cascales A, Sánchez-Vega B, Navarro N, Pastor-Quirante F, Corral J, Vicente V, de la Peña FA.

Int J Cardiol. 2012 Feb 9;154(3):282-6. doi: 10.1016/j.ijcard.2010.09.046. Epub 2010 Oct 25.

PMID:
20974500
10.

Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders.

Antón AI, González-Conejero R, Roldán V, Quiroga T, Sánchez-Vega B, Corral J, Vicente V, Mezzano D.

Ann Hematol. 2010 Nov;89(11):1147-54. doi: 10.1007/s00277-010-1000-7. Epub 2010 Jun 9.

PMID:
20532885
11.

Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels.

Antón AI, Teruel R, Corral J, Miñano A, Martínez-Martínez I, Ordóñez A, Vicente V, Sánchez-Vega B.

Haematologica. 2009 Apr;94(4):589-92. doi: 10.3324/haematol.2008.000604. Epub 2009 Feb 19.

12.

Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).

Sánchez-Vega B, Gandhi V.

Br J Haematol. 2009 Mar;144(6):856-64. doi: 10.1111/j.1365-2141.2008.07549.x. Epub 2008 Dec 26.

13.

Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells.

Sánchez-Vega B, Krett N, Rosen ST, Gandhi V.

Mol Cancer Ther. 2006 Dec;5(12):3062-70.

14.
17.

A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors.

Brenner B, Sánchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J.

Blood. 1998 Dec 15;92(12):4554-9.

PMID:
9845520
18.

Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase.

Wu SM, Stafford DW, Frazier LD, Fu YY, High KA, Chu K, Sanchez-Vega B, Solera J.

Blood. 1997 Jun 1;89(11):4058-62.

PMID:
9166845

Supplemental Content

Loading ...
Support Center